STOCK TITAN

MindMed to Participate at the Benzinga Global Small Cap Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Mind Medicine (MindMed) (NASDAQ: MNMD) will participate in the Benzinga Global Small Cap Conference on December 8-9, 2021. CEO Robert Barrow will present a corporate update and engage in one-on-one investor meetings on December 9 at 4:00 p.m. ET. A webcast of the event will be available here and on MindMed's website for 30 days post-event. The company focuses on developing psychedelic therapies for addiction and mental illness.

Positive
  • None.
Negative
  • None.

NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will provide a corporate update and the Company's management will participate in one-on-one investor meetings at the Benzinga Global Small Cap Conference to be held virtually on December 8-9, 2021.

Details on the conference can be found below.

Format: Corporate update and one-on-one investor meetings
Date: Thursday, December 9, 2021
Time: 4:00 p.m. ET
Webcast: Click Here

The webcast will also be accessible in the "Investors" section of MindMed's website. MindMed will maintain an archived replay of the webcast on its website for 30 days after the conference.

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

For Media: media@mindmed.co
For Investors: ir@mindmed.co

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-at-the-benzinga-global-small-cap-conference-301436029.html

SOURCE Mind Medicine (MindMed) Inc.

FAQ

What is MindMed's participation in the Benzinga Global Small Cap Conference?

MindMed will participate in the Benzinga Global Small Cap Conference on December 8-9, 2021, with a corporate update and one-on-one investor meetings.

Who will represent MindMed at the conference?

CEO Robert Barrow will represent MindMed at the Benzinga Global Small Cap Conference.

When will MindMed's corporate update take place?

MindMed's corporate update will take place on December 9, 2021, at 4:00 p.m. ET.

Where can I watch the MindMed conference webcast?

The webcast can be accessed on the Benzinga event page and on MindMed's website in the Investors section.

What is the focus of MindMed's drug development?

MindMed focuses on developing psychedelic-inspired therapies to address addiction and mental illness.

Mind Medicine (MindMed) Inc. Common Shares

NASDAQ:MNMD

MNMD Rankings

MNMD Latest News

MNMD Stock Data

636.89M
73.33M
1.14%
57.45%
12.54%
Biotechnology
Medicinal Chemicals & Botanical Products
Link
United States of America
NEW YORK